WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S (SEHK:2269)

APAC company
add to virtual portfolio
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - 2269

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - 2269

  • Market CapHKD0.000m
  • SymbolSEHK:2269
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINKYG970081090

Company Profile

WuXi Biologics (“WuXi”) is a contract development and manufacturing organization, or “CDMO”, for biologic drugs. It was founded in 2010 as part of WuXi AppTec and listed on the Hong Kong Stock Exchange in 2017. WuXi provides comprehensive services from conception to commercialization, including drug discovery, clinical and commercial manufacturing, and various support services such as process validation, viral clearance studies, product and cell line characterization, stability studies, and others. It does not conduct clinical trials. WuXi reported CNY 4 billion of revenue in 2019 and a three-year CAGR of 59%. Revenue by geography was 54% from North America, 35% from China, and 8% from Europe. About 45% of its projects are pre-IND (that is prior to clinical testing) and 65% were post-IND.WuXi Biologics (Cayman) Inc is a provider of comprehensive, integrated and customized range of services for the discovery, development and manufacturing of biologics.

Latest 2269 news

Currently there for this company. Visit our news hub for other news .